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The field of pancreatic transplantation sustained an important loss with the 
premature passing of Dr. Robert J. Corry in February 2002. He was a brilliant 
surgeon, a gifted clinician, and an incredibly generous individual. His legacy 
of humanity and clinical excellence has served as an inspiration, and this 
chapter is dedicated to his memory. 
Traditionally, single center contributions to Clinical Transplants have tended 
to focus on a given center's cumulative outcomes over an extended time 
frame. In this chapter, however, we will juxtapose two very different and 
relatively novel experiences. The first comprises traditional pancreatic 
transplantation in Type I diabetics, utilizing a conceptually different approach 
to immunosuppression, and also describing the implementation of technical 
refinements designed to improve outcomes. The second includes pancreatic 
transplantation in the context of multi visceral transplantation. Both 
experiences offer new insights that may prove to be of interest to the 
transplant community. 
I. Pancreatic Transplantation Under a Regimen of Campath-lH® 
Preconditioning and Low-Dose Tacrolimus Monotherapy 
Dr. Corry's passlllg came just after the initiation of a new approach to 
immunosuppression after organ transplantation that was based upon two principles-
recipient preconditioning and minimal post-transplant immunosuppression. The initial 
experience with pancreatic transplantation under Thymoglobulin preconditioning has been 
previously published (1). This chapter will focus on a more recent experience, utilizing 
Campath-l H® preconditioning, that has been utilized for simultaneous pancreas-kidney 
(SPK), pancreas after kidney (P AK), and pancreas transplantation alone (PTA). The early 
results with this regimen in have been gratifying. 
Campath-IH® is a humanized anti-CD52 monoclonal antibody. A single dose (30 
mg) depletes greater than 99% of T -cells, as well as B-cells and monocytes for an extended 
period of time, and has allowed post-transplant maintenance immunosuppression with 
tacrolimus monotherapy (2-3). Two doses only of intravenous corticosteroids have been 
given prior to and during Campath-lH® administration, to prevent cytokine release. This 
immunosuppressive regimen has resulted in lower rates of rejection and complications in 
the early post-transplant period, without an increase in infectious complications, and with 
excellent patient satisfaction. 
This section of the chapter will also describe the refinement of the technical aspects 
of pancreatic transplantation, which have evolved since the re-initiation of whole organ 
pancreas transplantation described over 20 years ago by Dr. Starzl (4), and refined by Dr. 
Corry and others (5). These have led to a substantially decreased rate of thrombosis and 
other technical complications after pancreatic transplantation. 
Rationale and Patient Characteristics 
The combination of antibody preconditioning and minimal post-transplant 
immunosuppression, developed by Dr. Starzl, is based upon two principles: 1. T-cell 
depletion creates the optimal conditions for the promotion of tolerance, and 2. Excessive 
early post-transplant immunosuppression is potentially antitolerogenic. The induction of a 
donor-specific tolerance towards an allograft by T-cell depletion has been demonstrated in 
a number of animal models (6), and the abrogation of tolerance by calcineurin inhibitors 
and steroids is also well described (7-8). 
Thirty-seven consecutive pancreas transplants (20 SPK, lOP AK, and seven PTA) 
were performed utilizing Campath-1H® preconditioning between July 2003 and August 
2004. Campath-l H® was given intra-operatively. Two grams of intravenous 
methylprednisolone were administered, one prior to starting the Campath-l H®, and 
another at reperfusion. Twice daily oral tacrolimus was started at 12 hours after 
transplantation, with target l2-hour troughs between 10-15 ng/ml (Tablel). Follow up of 
these patients range from three to 16 months with mean follow up time of 7 months. 
Type I diabetics (c-peptide level <0.50) with end-stage renal disease, on dialysis or 
with a CrCI <20 mg/ml either received a simultaneous kidney-pancreas transplant (SPK) or 
staged pancreas after living donor kidney transplantation (PAK). Isolated pancreas 
transplantation (PTA) was performed in patients with hypoglycemic unawareness, keto-
acidosis, or difficult-to-control blood glucoses (Table 2). Other than the conventional 
contraindications of malignancy and infection, there were no absolute contraindications to 
transplantation, although the most common cause of nonlisting was significant cardiac 
disease. Pretransplant clearance by dobutamine echo or cardiac catheterization was 
performed on all recipients. Mean recipient age (Table 2) was 43 ± 7.9 years (range 19-59) 
with 19% of recipients being over 50 years of age. Mean donor age was 30.3 ± 13 years 
(range 12-61), with some 11% of donors over age 50. One patient underwent combined 
kidney-pancreas transplantation from a non-heart beating donor. Donor and recipient 
selection closely matches guidelines described by Dr. Corry and those published in the 
literature (9-10). The most important determinants of pancreas allograft use in Pittsburgh 
are surgeon visualization, cold ischemia time (goal <24 hrs), and donor lipase levels (peak 
< 500 IU/dl). 
Technical aspects of donor preparation and implantation 
The standard technique for pancreas transplantation at the Thomas E. Starzl 
Transplantation Institute is iliac artery/vein revascularization and enteric drainage using a 
side-to-side duodenojejunostomy. Separate lateral incisions are made for the pancreas 
and/or kidney. Pancreas retransplantation is performed through a mid-line incision. 
The use of stapling techniques has greatly simplified both the donor back-table 
preparation as well as graft implantation. On the back table, staples can be used to perform 
the splenectomy, to ligate the root of the mesentery (both of which are reinforced with 
locking 4-0 polypropylene) and to ensure hemostasis across the peri-pancreas fat or 
connective tissue. A Y -graft to the superior mesenteric artery and splenic artery is 
routinely used, although revascularization of the gastroduodenal artery has been performed 
in donor organs with a potentially compromised blood supply to the head of the pancreas 
(11), as in the case of a donor with a replaced right hepatic artery or in a simultaneous 
pancreas-small bowel harvest. 
The head of the pancreas allograft is implanted in a cephalad position with the tail 
placed in the pelvis. In this position the Y -graft and donor portal vein can be anastomosed 
to the external iliac vessels, and a loop of recipient jejunum can be mobilized to create a 
tension-free duodenoenterostomy. A 15-20 degree clock-wise rotation of the portal vein 
allows for optimal positioning of the pancreas. The duodenoenterostomy is perfornled with 
a circular staple inserted through the lumen of the distal duodenum, and the distal 
duodenum closed with an endo-GIA stapler (12). The duodeno-enterostomy is reinforced 
with a row of 4-0 silk Lembert sutures. This technique is equally effective on the left or 
right side of the recipient. 
Outcomes 
Patient survival. The overall one-year actuarial patient survival for all patients in this 
series was 100 % (Figure 1). 
Pancreas survival. The actuarial pancreas survival at one year was 94% (35/37; Figure 
1). Two pancreata were lost, both of which were in SPK transplants. One pancreas was 
emergently removed nine months after transplant because of a bleeding pseudoaneurysm, 
although the allograft was functioning normally. The other pancreas came from a donor 
with pancreatitis (lipase 900s), which promptly thrombosed on POD 1 day. 
Kidney survival. The actuarial kidney survival in the SPK group at one year was 90% 
(18/20; Figure 1). A single kidney was lost to combined cellular and humoral rejection 
unresponsive to further Campath-l H® treatment and plasmapheresis with intravenous 
immunoglobulin. The other kidney thrombosed six weeks after simultaneous kidney and 
pancreas transplantation. Both pancreases are functioning well. No kidney allograft was 
lost in the PAK group. 
Rejection. Routine monitoring of amylase, lipase and creatinine were performed to 
monitor the pancreas and renal allografts. Suspicion of rejection was usually confirmed by 
an ultrasound-guided percutaneous biopsy and histological examination. 
The overall rate of rejection was 22% (8/37; Figure 2). Six of seven responded to a 
methylprednisolone bolus (1 gm) and increased tacrolimus doseages. One kidney was lost 
as described above. Interestingly, all rejection episodes were preceded by tacrolimus 
trough levels <9.0 for an extended period of time (five-seven days). Allograft rejection 
was not observed in pancreases or kidneys if the tacrolimus was> 1 0 ng/m!. 
Complications. The overall complication rate in the pancreas transplants (Figure 3) was 
22% (8 of 37) and included thrombosis--5% (1 kidney and 1 pancreas in 2 SPK 
recipients); anastomotic fistula--5% (l SPK, 1 PTA); pancreatitis--3%(l SPK); bleeding 
requiring re-exploration--8% (2 SPK, I P AK). The thrombosis and anastomotic leak 
occurred prior to the implementation of the technique described above. In 30 subsequent 
patients (not all are included in this report because of <3 month follow-up), no thrombosis 
and no tistulas have been seen. 
Discussion 
One of the major advantages of both the immunosuppressive regimen described here and 
the technical refinements that have been developed is their great simplicity. This is a safe 
and straightforward immunosuppressive regimen, with a low rate of rejection, a low rate of 
infectious complications, and a low rate of technical complications. In contrast to kidney 
transplantation alone, weaning to spaced dosing has proceeded much more slowly, given 
the consequences associated with late rejection. This approach is very well tolerated. 
While more follow up will be required to assess the long-term outcomes, this regimen 
appears to have substantial potential in the care of patients undergoing pancreatic 
transplantation. 
II. Pancreatic Transplantation En-Bloc with Visceral Grafts 
With the recent evolution of intestinal transplantation, the pancreas has frequently been 
transplanted en-bloc with the intestine, liver and other abdominal viscera. In contrast to 
combined pancreas-kidney and solitary pancreas transplantation, the pancreas is generally 
included in the multivisceral graft for non-diabetic indications. The objective of this report 
is to identify the indications for the procedure and its potential impact on the current United 
Network of Organ Sharing (UNOS) pancreatic transplant coding system and database. The 
immunogenicity and functional survival of the pancreas transplanted en-bloc with the other 
abdominal visceral organs will also be addressed. 
Technical Evolution 
Because of the embryonic origin of the pancreas, the gland shares its blood supply with the 
liver and intestine (Figure 2) (13). Accordingly, a few technical challenges were faced with 
the development of intestinal, liver-intestinal, and multivisceral transplantation. The 
successful simultaneous recovery of intestinal, pancreatic, and hepatic grafts from the 
same donor for transplantation to different recipients has been recently described and 
published (13). In the same article, the technique of en-bloc intestinal and pancreas 
transplantation was described for the first time with an illustration of the back table 
procedure (Figure 3) (13). The procedure of combined liver and intestinal transplantation 
has evolved over the last decade to preserve the duodenum and pancreas en-bloc with the 
liver and intestine. The rationale of maintaining continuity of the hepatobiliary system with 
the gut was to avoid the potential risks of biliary reconstruction and maximize the 
absorptive functions of the transplanted intestine (Figure 4). The pancreas has also been 
part of the modified (Figure 5A) (13) and full multivisceral transplantation (Figure 5B) (13) 
since the development of the procedure. However, a recent modification has been 
introduced to patients who have a benign disease of their foregut organs (Figure 6) (14). 
Recipient Operation 
Most of the patients who require intestinal and multi visceral transplantation with inclusion 
of the pancreas are critically ill and have multiple complex medical issues. The mean 
number of abdominal surgeries prior to transplantation was 4 ± 4 with a range of 0 to 25. 
In addition, these patients can lose their abdominal domain and frequently require 
reconstruction of their abdominal wall. 
The arterial reconstruction of the intestinal and multivisceral grafts is uniformly established 
through placement of an infrarenal aortic graft. The venous drainage of the combined 
intestinal/pancreatic and modified (without liver) multivisceral transplantation is 
commonly into the native portal system. However, in 2 recipients, the drainage was into the 
recipient vena cava. When the pancreas is part of a liverlintestinal and full multivisceral 
graft, continuity of the portomesenteric venous system is maintained as shown in Figure 4, 
5, and 6. Obviously, all pancreatic grafts were drained enteric ally and orthotopically. 
Indications 
The whole pancreas was transplanted en-bloc in 78 (32%) out of a total of 246 consecutive 
primary cadaveric abdominal visceral transplantations that were performed at our 
institution over the last 13 years. Of these, 43 were adults and 35 were children with a 
mean age of 40.5 ± 10.1 years, and 4.8 ± 5.8 years, respectively. Included with the 
pancreas was the intestine in 4 (5%) grafts, stomach and intestine in 14 (18%) grafts, liver 
and intestine in 28 (36%) grafts, and stomach, intestine and liver in the remaining 32 (41 %) 
grafts. The primary indications for inclusion of the pancreas were technical in 32 (41 %), 
vascular thrombosis in 18 (23 %), gastrointestinal dysmotility in 13 (17%), gut neoplasm in 
10 (13%), trauma in 3 (4%), and diabetes in the remaining 2 (2%) recipients. Insulin 
dependent diabetes was also an associated disorder in another 2 patients, giving a total of 4 
(5%) recipients who were diabetic prior to transplantation. Most of the recipients were non-
diabetic, and the indications for inclusion of the pancreas were mainly technical and 
vascular insufficiency. 
Donor Characteristics 
All donors were deceased and hemodynamically stable. The mean age was 15.7 ± 13.8 with 
a range of 3 days to 50 years. All but 2 allografts were ABO identical. Human leukocyte 
antigen (HLA) matching was random, with no cases of zero -A, -B, -DR mismatches. T 
and B lymphocytotoxic cross-matches were positive after dithiothreitol (DTT) treatment in 
13 (17%) patients. Because of the reported adverse effects of positive donor CMV serology 
on outcome, attempts were made in the recent cases to avoid using CMV seropositive 
intestinal donors for CMVseronegative recipients, particularly those who did not need 
replacement of the native liver (15). Management policies and retrieval operations have 
been described previously (16,17,18). No attempts were made to treat the donor with anti-
lymphocyte preparations. However, the intestinal component of 17 (22%) grafts were 
irradiated ex-vivo with a single dose of7.5 Gy. In addition, donor bone marrow cells were 
given intravenously to 25 (32%) recipients within the first 24 hours after allograft 
reperfusion at 2.4 - 9 X 10 8/kg BW. The University of Wisconsin (UW) solution was used 
for graft preservation in all but the first case, with a mean cold ischemia time (CIT) of 8.9 ± 
1. 7 hours. 
Immunosuppression 
Immunosuppression has evolved since the beginning of the program because of the high 
risk of intestinal allograft rejection. Tacrolimus-based immunosuppression was the 
underpinning of intestinal and mulitivisceral transplantation, and was used for all 78 
recipients. With the initial 14 (18%) patients, prednisone was added from the outset as a 
second agent. Induction therapy was utilized between 1995 and 2001 in 23 (29%) patients 
with cyclophosphamide in 3 and dac1izumab in 20 cases. A tolerogenic protocol was 
initiated in July of 200 1 with recipient pretreatment and post-transplant tacrolimus 
monotherapy. In 41 pretreated recipients, Thymoglobulin was used in 40 patients and 
Campath 1 H was used in the remaining case. Azathioprine, mycophenolate mofetil, or 
sirolimus were added as adjunct maintanence immunosuppression agents in selected cases 
at different time periods. In all patients but the first 8 recipients, prostaglandin EI was 
infused intravenously during the early postoperative period. Episodes of rejection were 
initially treated with steroids and adjustments of tacrolimus dosing. OKT3, Thymoglobulin, 
or Campath 1 H were used to treat steroid-resistant or severe rejection episodes. Details of 
the immunosuppressive protocols and drug dosage are described elsewhere (15, 19). 
Survival Outcome 
With a mean follow up of30 ± 26 months (0.3 - 116) and as of August 2004,52 pancreatic 
recipients with intestinal and multivisceral transplantations are alive, for an overall survival 
rate of 67%. The causes of death were infection (n= 11), PTLD (n=5), rejection (n=4), 
technical (n=3), GVHD (n=l) and others (n=2). Another 5 grafts were lost due to primary 
non-function in 2, arterial thrombosis in 2, and mycotic pseudoaneurysm in the remaining 
one. The actuarial patient survival was 81 % at 1 year and 77% at 5 years with pancreatic 
functional survival rates 0[76% and 62%, respectively. Despite patient complexity, one-
year survival has recently improved to 91 %. The recent improvement in outlook may be 
related to technical innovations, early viral detection, allograft immune-modulation, and 
recipient pretreatment. 
Pancreatic Rejection 
Despite the high immunogenicity of the concomitantly transplanted intestine, high degree 
of HLA mismatch, and transplanting the pancreas across a positive cytotoxic cross-match, 
only 6 (8%) pancreatic glands experienced mild to moderate acute rejection simultaneously 
with the intestine and/or liver allograft. The diagnosis was made based on clinical and 
biochemical data, and all episodes were successfully treated with steroids and/or anti-
lymphocytic agents. Chronic rejection was diagnosed on histopathologic examination of an 
explanted graft or an autopsy specimen on 3 (4%) occasions. These rates of acute and 
chronic pancreatic rejection are significantly lower than those observed in the 
simultaneously transplanted intestine. 
Preconditioning and Successful Weaning 
With recipient pretreatment, patient and graft survival have significantly improved, with a 
one-year patient survival of94% and a graft survival of90%. There has been no significant 
increase in morbidity, with a low risk of opportunistic infections, including viral infections. 
Attempts of weaning with spaced doses of tacrolimus monotherapy were successful in 49% 
(n=20) of the pretreated recipients. With a mean follow up of 19 ± 7 (range: 10 -35) 
months, 9 patients are on a single daily dose oftacrolimus, 3 on every other day, 2 on three 
times per week, and 6 on two times per week. There is no single example of graft loss to 
acute or chronic rejection because of weaning. 
Discussion 
En-bloc pancreas transplantation is common with intestinal and multivisceral 
transplantation. Diabetes is a rare indication for inclusion of the pancreatic gland. The 
lower risk of graft thrombosis is mainly related to the establishment of a large size 
infrarenal aortic graft and the common use of a Carrel patch during the back table arterial 
reconstruction. The gland is immunologically protected by the concomitantly transplanted 
organs, particularly the liver, despite the co-existence of high immunologic risk factors, 
including a high degree of HLA mismatching and pre-existing antibodies. 
Summary: 
1. Campath-l H ® preconditioning with tacrolimus mono therapy is an effective 
immunosuppressive regimen for pancreas transplantation, with acceptable patient 
and graft survival rates early after post-transplantation. 
2. Rejection rates are low under this protocol if the tacrolimus level IS kept 
consistently> 1 0 ng/ml. 
3. This immunosuppressive protocol, combined with recent technical refinements, has 
resulted in lower rates of thrombosis and overall complications. 
4. Pancreatic transplantation en bloc with visceral grafts has the following unique 
features: 
A. Diabetes is a rare indication, and HLA matching is not required. 
B. The gland is immunologically protected by the simultaneously transplanted 
visceral organs. 
C. Disease gravity, surgical complexity and gut alloimmunity influence the 
overall pancreatic allograft survival. 
D. The current UNOS listing criteria and data registry should be modified for 
obvious logistic and scientific reasons. 
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The embryonic origin of the liver, pancreas and alimentary canal. Note the shared axial 
blood supply and its segmental distribution, CA, celiac axis; GDA, gastroduodenal artery; 
IPDA, inferior pancreaticduodenal artery; SA, splenic artery; SMA, superior mesenteric 
artery. 
Figure 3 Back table vascular reconstruction of the composite intestinal-pancreatic 
allograft. Note continuity of the pancreas, duodenum, and small intestine 
with intact vascular pedicle, CIA, common iliac artery, CrY, common iliac 
vein; EIA, external iliac artery; IIA, internal iliac artery; PV, portal vein. 
Figure 4 
A. Combined liver and intestine without the duodenum and pancreas. 
B. Combined liver and intestine en-bloc with duodenum and pancreas. Note continuity 
of the hepatobiliary system with the duodenum. Resection of the left lobe of the 
liver was performed because of loss of the abdominal domain of the recipient. 
A. B. 
Figure 5 
Modified multivisceral graft that contains stomach, 
Duodenum, pancreas, and small intestine. Note preservation of 
The gastroepiploic arcade and left gastric pedicle including the 
Left gastric vein (LGV). Inset: Venous drainage of the composite 
Visceral graft to the side of the recipient superior mesenteric vein 
(SMV) stump by using the donor common iliac vein as an extension 
graft without compromising the recipient portal venous flow during 
graft implantation. PV, portal vein; SV splenic vein. 
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B. Full multivisceral transplant 
Figure 6 
A. Transplantation ofa modified multivisceral graft (unshaded organs) containing the 
pancreas and all of the hollow intraabdominal viscera in continuity from the 
esophagogastric junction to the terminal ileum. The native liver, spleen, pancreas, and 
a C loop of duodenum have been retained.Biliary drainage from the native liver as 
well as from both pancreases was accomplished with a side-to-side host-to-graft 
duodenal anastomosis. The insert shows preservation of the donor splenic (DSA) and 
left gastric (DLGA) arteries (with Carrel patch) with ligation of the donor hepatic 
artery (DHA) stump. Note that an interposition arterial graft was initially 
anastomosed to the recipient infrarenal aorta and before allograft implantation. RSA, 
recipient splenic artery; RSV, recipient splenic vein; RBD, recipient bile duct; RPV, 
recipient portal vein; DSMV, donor superior mesenteric vein; DSMA, donor superior 
mesenteric al1ery. 
B. The use of a modified multivisceral graft (stomach, duodenum, pancreas, 
and small bowel) after abdominal visceral exenteration with preservation 
of the host liver and spleen (shaded organs). The porto splenic circulation 
is maintained intact during graft insertion and the preserved spleen 
protects the patient from the risk ofposttransplant lymphoproliferative 
disease. This modified multi visceral transplantation has been used to treat 
recipients with massive gstrointestinl polyposis and extensive Crohn's 
disease. Note the duct-to-duct biliary reconstruction, RSA, recipient 
splenic artery; RSV, recipient splenic vein; RBD, recipient bile duct; 
DSA, donor splenic artery: DLGA, donor left gastric artery; DBD, donor 
bile duct. 
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